| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | |
|---|---|---|---|---|
| Total income tax expense | 121 | 64 | 41 | |
| Net loss attributed to shareholders for the period | -7,977 | -15,695 | -10,724 | |
| Foreign currency translation adjustment | -808 | 2,713 | 103 | |
| Net loss and other comprehensive loss for the period | -8,785 | -12,982 | -10,621 | |
| Earnings per share, basic | 0.26 | 0.52 | 0.36 | |
| Earnings per share, diluted | 0.26 | 0.52 | 0.36 | |
| Weighted average number of shares outstanding, basic | 30,104,497 | 30,053,142 | 30,041,735 | |
| Weighted average number of shares outstanding, diluted | 30,104,497 | 30,053,142 | 30,041,735 | |
Profound Medical Corp. (PROF)
Profound Medical Corp. (PROF)